{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:58:18Z","timestamp":1785527898449,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Association of Women Surgeons Foundation Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In estrogen receptor (ER)-positive, HER2-negative breast cancer, systemic therapy decisions are often made on the biomarker status of the primary tumor, along with the Oncotype DX Recurrence Score\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (RS). Biomarker testing of nodal metastases is not routine, despite reported receptor discordance. We quantified ER\/PR\/HER2 discordance between primary tumors and axillary lymph node metastases and evaluated associations with RS and clinicopathologic features.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective study of women with stage II\u2013III, ER-positive, HER2-negative, node-positive invasive breast cancer who underwent upfront surgery and Oncotype DX testing of the primary tumor between 2016 and 2020. ER, PR, and HER2 immunohistochemistry (IHC) was performed on archived nodal metastases. Discordance in ER\/PR percent positivity and HER2 IHC score between primary and lymph node metastases was scored ordinally from 0 to 2 for no, mild, or marked difference, respectively. Associations with RS, tumor and nodal burden, and treatment were analyzed using standard parametric and nonparametric tests with statistical significance set at\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 555 patients with RS testing, 91 patients met inclusion criteria and 73 had available nodal tissue. Discordance in at least one receptor was high overall, occurring in 56\/73 (77%) cases. The discordance rate for ER was 15%, PR was 32%, and HER2 was 66% (58% mild, 8% marked). One case demonstrated loss of ER positivity in the node, and 14 demonstrated loss of PR positivity in the node; no primary HER2-negative tumor converted to HER2-positive (IHC 3+) disease in the node. Greater amount of HER2 discordance was associated with larger primary tumors and larger size of nodal metastatic deposits. Higher RS correlated with lower primary ER and PR expression and higher volume of nodal burden (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 for each) but was not significantly associated with receptor discordance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Receptor discordance between primary tumors and nodal metastases is common, with most shifts occurring within the HER2-spectrum. There was a trend toward higher RS and ER or HER2-receptor discordance. HER2 discordance was also associated with larger tumor size and larger size of nodal metastasis. As strategies emerge to target HER2-low cohorts and to include ER-low\/HER2-negative disease within treatment regimens for TNBC, it may become important to consider receptor testing of nodal disease in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-08009-0","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:58:24Z","timestamp":1782129504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer"],"prefix":"10.1007","volume":"217","author":[{"given":"Serena","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumkum","family":"Vadehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Levee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mediget","family":"Teshome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hong","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4572-075X","authenticated-orcid":false,"given":"Nimmi S.","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"8","key":"8009_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/S00432-025-06271-1","volume":"151","author":"P Kr\u00f3lewska-Daszczy\u0144ska","year":"2025","unstructured":"Kr\u00f3lewska-Daszczy\u0144ska P, Englisz A, Morawiec ML, Mi\u015bkiewicz J, Go\u0142\u0119bski M, Mielczarek-Palacz A (2025) The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis. J Cancer Res Clin Oncol 151(8):233. https:\/\/doi.org\/10.1007\/S00432-025-06271-1","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"8009_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4274\/EJBH.GALENOS.2023.2023-6-3","volume":"20","author":"C Karaali","year":"2023","unstructured":"Karaali C, Emiro\u011flu M, De\u011firmenci M, Keser M, Salimo\u011flu S, Talu CK (2023) The Clinical and Pathological Characteristics That Differentiate Cases With Low Estrogen Receptor Expression From Triple-Negative Breast Cancer. Eur J Breast Health 20(1):19. https:\/\/doi.org\/10.4274\/EJBH.GALENOS.2023.2023-6-3","journal-title":"Eur J Breast Health"},{"issue":"7","key":"8009_CR3","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3390\/MEDICINA61071280","volume":"61","author":"OM Burciu","year":"2025","unstructured":"Burciu OM, Merce AG, Cerbu S et al (2025) Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning. Med (B Aires) 61(7):1280. https:\/\/doi.org\/10.3390\/MEDICINA61071280","journal-title":"Med (B Aires)"},{"issue":"7","key":"8009_CR4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/JCO.2007.12.9437","volume":"26","author":"M Dowsett","year":"2008","unstructured":"Dowsett M, Allred C, Knox J et al (2008) Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 26(7):1059\u20131065. https:\/\/doi.org\/10.1200\/JCO.2007.12.9437","journal-title":"J Clin Oncol"},{"issue":"2","key":"8009_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/JAMAONCOL.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R et al (2024) Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol 10(2):227\u2013235. https:\/\/doi.org\/10.1001\/JAMAONCOL.2023.5033","journal-title":"JAMA Oncol"},{"issue":"12","key":"8009_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update. J Clin Oncol 38(12):1346\u20131366. https:\/\/doi.org\/10.1200\/JCO.19.02309","journal-title":"J Clin Oncol"},{"key":"8009_CR7","doi-asserted-by":"publisher","first-page":"100896","DOI":"10.1016\/J.LANEPE.2024.100896","volume":"40","author":"H Jernstr\u00f6m","year":"2024","unstructured":"Jernstr\u00f6m H, Ryd\u00e9n L (2024) Into the twilight zone \u2013 should ER-low breast cancer be treated as triple negative breast cancer? Lancet Reg Health - Europe 40:100896. https:\/\/doi.org\/10.1016\/J.LANEPE.2024.100896","journal-title":"Lancet Reg Health - Europe"},{"issue":"OCT","key":"8009_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/FONC.2019.01124","volume":"9","author":"A Godoy-Ortiz","year":"2019","unstructured":"Godoy-Ortiz A, Sanchez-Mu\u00f1oz A, Parrado MRC et al (2019) Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. Front Oncol 9(OCT):1124. https:\/\/doi.org\/10.3389\/FONC.2019.01124","journal-title":"Front Oncol"},{"key":"8009_CR9","doi-asserted-by":"publisher","unstructured":"Qureshi Z, Altaf F, Jamil A, Siddique R, Fatima E (2024) Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2\u2009+\u2009and HER2-low Breast Cancer. Am J Clin Oncol. Published online July 2. https:\/\/doi.org\/10.1097\/COC.0000000000001126","DOI":"10.1097\/COC.0000000000001126"},{"issue":"1","key":"8009_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"issue":"3","key":"8009_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-023-07151-3","volume":"203","author":"M Gaudio","year":"2024","unstructured":"Gaudio M, Jacobs F, Benvenuti C et al (2024) Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer. Breast Cancer Res Treat 203(3):487\u2013495. https:\/\/doi.org\/10.1007\/s10549-023-07151-3","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"8009_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-018-0090-6","volume":"4","author":"CE Geyer","year":"2018","unstructured":"Geyer CE, Tang G, Mamounas EP et al (2018) 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. npj Breast Cancer 2018 4(1):1. https:\/\/doi.org\/10.1038\/s41523-018-0090-6","journal-title":"npj Breast Cancer 2018"},{"issue":"3","key":"8009_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/JAMAONCOL.2019.4794","volume":"6","author":"JA Sparano","year":"2020","unstructured":"Sparano JA, Gray RJ, Makower DF et al (2020) Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol 6(3):367\u2013374. https:\/\/doi.org\/10.1001\/JAMAONCOL.2019.4794","journal-title":"JAMA Oncol"},{"issue":"25","key":"8009_CR14","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMOA2108873\/","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR et al (2021) 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 385(25):2336\u20132347. https:\/\/doi.org\/10.1056\/NEJMOA2108873\/SUPPL_FILE\/NEJMOA2108873_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"issue":"1","key":"8009_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s12032-013-0798-y","volume":"31","author":"Zxiang Yao","year":"2014","unstructured":"Yao Zxiang, Lu Ljie, Wang Rjue et al (2014) Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol 31(1):798. https:\/\/doi.org\/10.1007\/s12032-013-0798-y","journal-title":"Med Oncol"},{"key":"8009_CR16","doi-asserted-by":"publisher","unstructured":"Kuncman W, Orzechowska M, Kuncman \u0141, Kordek R, Taran K (2021) Intertumoral heterogeneity of primary breast tumors and synchronous axillary lymph node metastases reflected in IHC-assessed expression of routine and nonstandard biomarkers. Front Oncol 11. https:\/\/doi.org\/10.3389\/fonc.2021.660318","DOI":"10.3389\/fonc.2021.660318"},{"key":"8009_CR17","doi-asserted-by":"publisher","unstructured":"Baro\u0161 IV, Tanaskovi\u0107 N, Pellas U, Eri \u017d, Tadi\u0107 Latinovi\u0107 L, Tot T (2019) Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients. Bosn J Basic Med Sci. Published online April 2. https:\/\/doi.org\/10.17305\/bjbms.2019.3970","DOI":"10.17305\/bjbms.2019.3970"},{"issue":"4","key":"8009_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/S10585-023-10214-W","volume":"40","author":"S Janeva","year":"2023","unstructured":"Janeva S, Parris TZ, Krabbe E et al (2023) Clinical relevance of biomarker discordance between primary breast cancers and synchronous axillary lymph node metastases. Clin Exp Metastasis 40(4):299. https:\/\/doi.org\/10.1007\/S10585-023-10214-W","journal-title":"Clin Exp Metastasis"},{"key":"8009_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2147\/BCTT.S366122","volume":"15","author":"Y Shirman","year":"2023","unstructured":"Shirman Y, Lubovsky S, Shai A (2023) HER2-Low Breast Cancer: Current Landscape and Future Prospects. Breast Cancer: Targets Therapy 15:605. https:\/\/doi.org\/10.2147\/BCTT.S366122","journal-title":"Breast Cancer: Targets Therapy"},{"issue":"4","key":"8009_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/MEDICINA61040644","volume":"61","author":"AM Shaaban","year":"2025","unstructured":"Shaaban AM, Kaur T, Provenzano E (2025) HER2-Low Breast Cancer\u2014Current Knowledge and Future Directions. Med (B Aires) 61(4):644. https:\/\/doi.org\/10.3390\/MEDICINA61040644","journal-title":"Med (B Aires)"},{"issue":"22","key":"8009_CR21","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R et al (2024) DESTINY-Breast06 Trial Investigators. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med 391(22):2110\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa2407086","journal-title":"N Engl J Med"},{"issue":"11","key":"8009_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/COC.0000000000001126","volume":"47","author":"Z Qureshi","year":"2024","unstructured":"Qureshi Z, Altaf F, Jamil A, Siddique R, Fatima E (2024) Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2\u2009+\u2009and HER2-low Breast Cancer An Updated Systematic Review and Meta-Analysis of Clinical Trials. Am J Clin Oncology: Cancer Clin Trials 47(11):535\u2013541. https:\/\/doi.org\/10.1097\/COC.0000000000001126","journal-title":"Am J Clin Oncology: Cancer Clin Trials"},{"key":"8009_CR23","doi-asserted-by":"publisher","unstructured":"Gaudio M, Jacobs F, Benvenuti C et al (2023) Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer. Breast Cancer Res Treat 203(3):487\u2013495. https:\/\/doi.org\/10.1007\/S10549-023-07151-3","DOI":"10.1007\/S10549-023-07151-3"},{"issue":"12","key":"8009_CR24","doi-asserted-by":"publisher","first-page":"105907","DOI":"10.1016\/J.ESMOOP.2025.105907","volume":"10","author":"F Cherifi","year":"2025","unstructured":"Cherifi F, Cabel L, Bousrih C et al (2025) PROMENADE: pembrolizumab for early ER-low\/HER2-negative breast cancer, real-world French cohort. ESMO Open 10(12):105907. https:\/\/doi.org\/10.1016\/J.ESMOOP.2025.105907","journal-title":"ESMO Open"},{"issue":"1","key":"8009_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/S13058-025-02179-3\/TABLES\/2","volume":"27","author":"S Steen","year":"2025","unstructured":"Steen S, Karlsson E, Bj\u00f6rnheden I et al (2025) Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study. Breast Cancer Res 27(1):213. https:\/\/doi.org\/10.1186\/S13058-025-02179-3\/TABLES\/2","journal-title":"Breast Cancer Res"},{"issue":"2","key":"8009_CR26","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso F, O\u2019Shaughnessy J, Liu Z et al (2025) Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2013 breast cancer: a randomized phase 3 trial. Nat Med 31(2):442\u2013448. https:\/\/doi.org\/10.1038\/s41591-024-03415-7","journal-title":"Nat Med"},{"issue":"1","key":"8009_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/J.1699-0463.1995.TB01074.X","volume":"103","author":"L Nedergaard","year":"1995","unstructured":"Nedergaard L, Haerslev T, Jacobsen GK (1995) Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS 103(1):20\u201324. https:\/\/doi.org\/10.1111\/J.1699-0463.1995.TB01074.X","journal-title":"APMIS"},{"issue":"6","key":"8009_CR28","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/annonc\/mdp427","volume":"21","author":"SJ Aitken","year":"2009","unstructured":"Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D (2009) Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21(6):1254\u20131261. https:\/\/doi.org\/10.1093\/annonc\/mdp427","journal-title":"Ann Oncol"},{"issue":"1\u20136","key":"8009_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1699-0463.1995.tb01074.x","volume":"103","author":"L Nedergaard","year":"1995","unstructured":"Nedergaard L, Haerslev T, Jacobsen GK (1995) Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS 103(1\u20136):20\u201324. https:\/\/doi.org\/10.1111\/j.1699-0463.1995.tb01074.x","journal-title":"APMIS"},{"issue":"6","key":"8009_CR30","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/annonc\/mdp427","volume":"21","author":"SJ Aitken","year":"2010","unstructured":"Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D (2010) Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21(6):1254\u20131261. https:\/\/doi.org\/10.1093\/annonc\/mdp427","journal-title":"Ann Oncol"},{"key":"8009_CR31","doi-asserted-by":"publisher","unstructured":"Yao ZX, Lu LJ, Wang RJ et al (2013) Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol 31(1):798. https:\/\/doi.org\/10.1007\/S12032-013-0798-Y","DOI":"10.1007\/S12032-013-0798-Y"},{"key":"8009_CR32","doi-asserted-by":"publisher","first-page":"660318","DOI":"10.3389\/FONC.2021.660318\/FULL","volume":"11","author":"W Kuncman","year":"2021","unstructured":"Kuncman W, Orzechowska M, Kuncman \u0141, Kordek R, Taran K (2021) Intertumoral Heterogeneity of Primary Breast Tumors and Synchronous Axillary Lymph Node Metastases Reflected in IHC-Assessed Expression of Routine and Nonstandard Biomarkers. Front Oncol 11:660318. https:\/\/doi.org\/10.3389\/FONC.2021.660318\/FULL","journal-title":"Front Oncol"},{"issue":"3","key":"8009_CR33","doi-asserted-by":"publisher","first-page":"242","DOI":"10.17305\/BJBMS.2019.3970","volume":"19","author":"IV Baro\u0161","year":"2019","unstructured":"Baro\u0161 IV, Tanaskovi\u0107 N, Pellas U, Eri \u017d, Latinovi\u0107 LT, Tot T (2019) Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients. Bosn J Basic Med Sci 19(3):242\u2013248. https:\/\/doi.org\/10.17305\/BJBMS.2019.3970","journal-title":"Bosn J Basic Med Sci"},{"key":"8009_CR34","doi-asserted-by":"publisher","unstructured":"Boolbol SK, Harshan M, Chadha M, et al (2019) Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score\u00ae test. 177:611\u2013618. https:\/\/doi.org\/10.1007\/s10549-019-05346-1","DOI":"10.1007\/s10549-019-05346-1"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08009-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:16:34Z","timestamp":1785521794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08009-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8009"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08009-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed by the UCLA Institutional Review Board (IRB), which deemed it to be exempt from IRB review under 45 CFR 46.104(d)(4) (secondary research using existing data\/specimens) (IRB 24\u2013000534, certified exempt on April 18, 2024). The research was conducted in accordance with the Declaration of Helsinki and applicable regulations; informed consent was waived per the exemption determination. Data were analyzed in a de-identified form.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to the publication of this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RC reports work as consultant\/speaker for the following companies: Gilead, Stemline, Astra Zeneca, Daiichi Sankyo Inc, Novartis, Pfizer, Arvinas, Roche, Natera, SAGA, Hologic, Tempus. RC reports research funding from Celcuity, Inc., Roche, Eli Lilly and Co. MT reports work as consultant for Elucent Medical, Inc. AB reports work as consultant for Pfizer, Novartis, Merck, Genentech, AstraZeneca\/Daiichi, Alyssum, Menarini, Gilead, Eli Lilly. NSK reports work as consultant for IceCure Medical, Inc., Aura Health Technologies, Elucent Medical, Inc. NSK reports research\/grant funding from: View Point Medical, Jonsson Comprehensive Cancer Center, Biotheranostics\/Hologic, Inc. All other authors have no disclosures.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"57"}}